CDC report highlights the gaps in care of hepatitis C treatment

Elion Ther­a­peu­tics, a biotech fo­cused on in­va­sive fun­gal in­fec­tions, has raised $81 mil­lion in a Se­ries B fund­ing round for its ear­ly-stage can­di­date, it an­nounced

Share this article Repotrectinib is approved by the US FDA to treat adults with locally advanced or metastatic ROS1-positive NSCLC. Credit: Chinnapong / Shutterstock.com. The

More than half of the can­cer cas­es the FDA is ex­am­in­ing as part of its CAR-T safe­ty in­ves­ti­ga­tion oc­curred with­in two years of treat­ment, ac­cord­ing